#

BHARAT BIOTECH

Coronavirus HIGHLIGHTS: Confident Of Getting EMA's Approval In A month For Covishield, Says SII Chief Adar Poonawalla

Brazil Govt Faces Probe For Choosing Bharat Biotech's Covaxin Deal Over 'Cheaper' Pfizer Vaccine | All About Controversy
Covaxin Phase 3 Trial Data Shows 77.8% Efficacy, Gets Approval From DCGI's Expert Panel
Coronavirus HIGHLIGHTS: Bharat Biotech Submitted COVAXIN's Phase 3 Clinical Trial Data To DCGI, Say Govt Sources
Covaxin Supplies At Rs 150/Dose ‘Non-Competitive Price, Not Sustainable’: Bharat Biotech Defends Higher Price
No Emergency Use Approval For Covaxin In US; Phase 3 Trial Data Expected To Be Published In 7-8 Days, Says Dr VK Paul

'More Info Required': WHO To Bharat Biotech As It Submits ‘90% Documents’ For Emergency Use Listing Of Covaxin

About us | Advertisement| Privacy policy

© Copyright@2024.ABP Network Private Limited. All rights reserved.